251 related articles for article (PubMed ID: 19344283)
1. RANKL inhibition: clinical implications for the management of patients with multiple myeloma and solid tumors with bone metastases.
Terpos E; Efstathiou E; Christoulas D; Roussou M; Katodritou E; Dimopoulos MA
Expert Opin Biol Ther; 2009 Apr; 9(4):465-79. PubMed ID: 19344283
[TBL] [Abstract][Full Text] [Related]
2. Receptor-Activator of Nuclear KappaB Ligand Expression as a New Therapeutic Target in Primary Bone Tumors.
Yamagishi T; Kawashima H; Ogose A; Ariizumi T; Sasaki T; Hatano H; Hotta T; Endo N
PLoS One; 2016; 11(5):e0154680. PubMed ID: 27163152
[TBL] [Abstract][Full Text] [Related]
3. RANKL inhibition for the management of patients with benign metabolic bone disorders.
Anastasilakis AD; Toulis KA; Polyzos SA; Terpos E
Expert Opin Investig Drugs; 2009 Aug; 18(8):1085-102. PubMed ID: 19558335
[TBL] [Abstract][Full Text] [Related]
4. The RANK/RANKL/OPG triad in cancer-induced bone diseases.
Dougall WC; Chaisson M
Cancer Metastasis Rev; 2006 Dec; 25(4):541-9. PubMed ID: 17180711
[TBL] [Abstract][Full Text] [Related]
5. [The role of RANK/RANKL and OPG in multiple myeloma].
Zdzisińska B; Kandefer-Szerszeń M
Postepy Hig Med Dosw (Online); 2006; 60():471-82. PubMed ID: 17013366
[TBL] [Abstract][Full Text] [Related]
6. Nuclear factor-kappa B ligand and osteoprotegerin levels in serum and gingival crevicular fluid in patients with bone metastases treated with zoledronic acid.
Inanc M; Kaynar L; Enhos S; Pala C; Karaca H; Berk V; Ozkan M; Sıvgın S; Eser B; Cetin M; Elmali F
Med Oncol; 2014 Mar; 31(3):837. PubMed ID: 24448976
[TBL] [Abstract][Full Text] [Related]
7. RANKL/RANK/OPG: new therapeutic targets in bone tumours and associated osteolysis.
Wittrant Y; Théoleyre S; Chipoy C; Padrines M; Blanchard F; Heymann D; Rédini F
Biochim Biophys Acta; 2004 Sep; 1704(2):49-57. PubMed ID: 15363860
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis.
Canon JR; Roudier M; Bryant R; Morony S; Stolina M; Kostenuik PJ; Dougall WC
Clin Exp Metastasis; 2008; 25(2):119-29. PubMed ID: 18064531
[TBL] [Abstract][Full Text] [Related]
9. Denosumab: RANKL inhibition in the management of bone loss.
Hamdy NA
Drugs Today (Barc); 2008 Jan; 44(1):7-21. PubMed ID: 18301800
[TBL] [Abstract][Full Text] [Related]
10. Clinical development of anti-RANKL therapies for treatment and prevention of bone metastasis.
Lipton A; Goessl C
Bone; 2011 Jan; 48(1):96-9. PubMed ID: 20950721
[TBL] [Abstract][Full Text] [Related]
11. [The role of RANK/RANKL/osteoprotegerin (OPG) triad in cancer-induced bone diseases: physiopathology and clinical implications].
Clézardin P
Bull Cancer; 2011 Jul; 98(7):837-46. PubMed ID: 21700551
[TBL] [Abstract][Full Text] [Related]
12. [Therapeutic agents for disorders of bone and calcium metabolism--Denosumab, a fully human monoclocal antibody-targeting RANKL as a therapy for cancer-induced bone diseases].
Mera K; Ito K
Clin Calcium; 2007 Jan; 17(1):37-46. PubMed ID: 17211092
[TBL] [Abstract][Full Text] [Related]
13. The high rate of bone resorption in multiple myeloma is due to RANK (receptor activator of nuclear factor-kappaB) and RANK Ligand expression.
Roux S; Mariette X
Leuk Lymphoma; 2004 Jun; 45(6):1111-8. PubMed ID: 15359989
[TBL] [Abstract][Full Text] [Related]
14. RANKL inhibition blocks osteolytic lesions and reduces skeletal tumor burden in models of non-small-cell lung cancer bone metastases.
Miller RE; Jones JC; Tometsko M; Blake ML; Dougall WC
J Thorac Oncol; 2014 Mar; 9(3):345-54. PubMed ID: 24496001
[TBL] [Abstract][Full Text] [Related]
15. Molecular pathways: osteoclast-dependent and osteoclast-independent roles of the RANKL/RANK/OPG pathway in tumorigenesis and metastasis.
Dougall WC
Clin Cancer Res; 2012 Jan; 18(2):326-35. PubMed ID: 22031096
[TBL] [Abstract][Full Text] [Related]
16. RANKL inhibition combined with tamoxifen treatment increases anti-tumor efficacy and prevents tumor-induced bone destruction in an estrogen receptor-positive breast cancer bone metastasis model.
Canon J; Bryant R; Roudier M; Branstetter DG; Dougall WC
Breast Cancer Res Treat; 2012 Oct; 135(3):771-80. PubMed ID: 22926264
[TBL] [Abstract][Full Text] [Related]
17. RANK ligand inhibition with denosumab for the management of osteoporosis.
Lewiecki EM
Expert Opin Biol Ther; 2006 Oct; 6(10):1041-50. PubMed ID: 16989586
[TBL] [Abstract][Full Text] [Related]
18. Receptor activator of nuclear factor-kappaB ligand and osteoprotegerin: potential implications for the pathogenesis and treatment of malignant bone diseases.
Hofbauer LC; Neubauer A; Heufelder AE
Cancer; 2001 Aug; 92(3):460-70. PubMed ID: 11505389
[TBL] [Abstract][Full Text] [Related]
19. RANK ligand as a therapeutic target for bone metastases and multiple myeloma.
Roodman GD; Dougall WC
Cancer Treat Rev; 2008 Feb; 34(1):92-101. PubMed ID: 17964729
[TBL] [Abstract][Full Text] [Related]
20. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases.
Hofbauer LC; Schoppet M
JAMA; 2004 Jul; 292(4):490-5. PubMed ID: 15280347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]